Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05761431
Other study ID # SYHX2008-001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 2, 2023
Est. completion date June 28, 2023

Study information

Verified date October 2023
Source CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-centre, single-dose, dose-escalation, placebo and positive drug-controlled Phase I clinical study in healthy Chinese subjects to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of octreotide injection in healthy Chinese subjects.


Description:

This single centre study will be comprised of 6 cohorts. The single ascending dose part is comprises of 4 cohorts(5 mg, 10 mg, 20 mg, 30 mg). The other 2 cohorts are octreotide long-acting release ( Sandostatin LAR® ) 20 mg and Sandostatin® 0.1 mg.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date June 28, 2023
Est. primary completion date June 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years to 45 Years
Eligibility Inclusion Criteria: 1. Healthy, adult, male and female subjects, 22-45 years of age, inclusive, at screening; 2. Body weight=50 kg in male subjects or=45 kg in female subjects, with BMI 19.0 - 28.0 kg/m^2 (inclusive); 3. Good health without history of cardiovascular vascular, liver, kidney, respiratory system, digestive, nervous, blood, immune, cancer, endocrine disease or any system diseases that have completely recovery or no clinical significance by investigator's assessment; 4. No clinically relevant findings in the physical examination, ECG, abdominal ultrasonography, vital signs, laboratory examination by investigator's assessment; 5. Informed consent documents signed by subjects prior the study, and subjects could be able to read, comprehend the procedure or the adverse reaction about the trial; 6. Subjects (including female and male subjects) have no pregnancy plan and sperm (egg) donation plan and voluntarily take effective contraceptive methods from signing the informed consent form until 3 months after administration of investigational product. Exclusion Criteria: 1. The subject has a history of sensitivity (such as asthma, urticaria, eczema, etc), or has a known hypersensitivity to any of the test materials or related compounds, or has allergic constitution; 2. The female subject of childbearing potential, is pregnant (as based on test results in the screening period) or is breast feeding; 3. The subject with any one of HBsAg, hepatitis C antibody, anti-HIV antibody and antibody of treponema pallidum positive; 4. The subject with chronic or acute gastrointestinal disease (such as dyspepsia, gastro-oesophageal reflux, gastric bleeding or peptic ulcer, etc), or has a history of gallbladder disease (such as gallstone, cholecystectomy, etc) and other diseases; 5. The subject has a history of acupuncture syncope or blood phobia, or has difficulty with vein blood collection or venipuncture; 6. The subject has difficulty with subcutaneous administration; 7. The subject has a history of drug abuse or dependence, or has a positive result of drug abuse test in urine; 8. The subject intake more than 14 units alcohol within 3 months before administration of investigational product (1 unit=360 mL of beer, or 45 mL spirits, or 150 mL grape wine), or can't control to drink alcohol; 9. The subject smoke more than 5 cigarettes per day within 3 months before administration of investigational product, or smoke within 48h before administration of investigational product, or are unwilling to stop any tobacco products; 10. The subject has a history of hospitalization or surgical operation within 3 months before screening; 11. The subject has participated in other clinical trials within 3 months before administration of investigational product; 12. The subject donated blood or lost blood >400 mL (except female physiological period) within 3 months before screening; 13. The subject received prescription or non-prescription drugs within 28 days before administration of investigational product, including the drug effect on growth hormone and insulin-like growth factor (such as epinephrine, cholinergic drugs, etc); or received dietary supplements within 7 days before administration of investigational product (such as vitamin, protein powder, etc); 14. The subject with consumption of food or beverage containing caffeine or xanthine within 72 hours before administration of investigational product (such as coffee, tea, cola, chocolate, etc), or grapefruit fruit, or products containing grapefruit ingredients; 15. The subject has received any products containing alcohol within 48 hours before administration of investigational product or has a positive result of breath alcohol test; 16. According to the investigator's judgment, there are other situations that are not suitable for participating in this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SYHX2008 injection
Subcutaneous administration on Day 1.
Octreotide Acetate Microspheres for Injection injection
Intramuscular administration on Day 1.
Sandostatin ® injection
Subcutaneous administration on Day 1.
Placebo to SYHX2008 injection
Subcutaneous administration on Day 1.

Locations

Country Name City State
China Beijing Anzhen Hospital, Capital Medical University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of adverse events Throughout the study period, with an average of 60 days.
Secondary Area under the plasma concentration-time curve (AUC) AUC from pre-dose to time 't' (AUC[0-t]) and pre-dose to infinite time (AUC[0-infinity]) of Octreotide Pre-dose, 0.5 hour, 1 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour, 48 hour, 96 hour, 168 hour, 336 hour, 576 hour, 1008 hour, 1416 hour.
Secondary Maximum plasma concentration (Cmax) Maximum octreotide plasma concentration (Cmax) of Octreotide Pre-dose, 0.5 hour, 1 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour, 48 hour, 96 hour, 168 hour, 336 hour, 576 hour, 1008 hour, 1416 hour.
Secondary Time to maximum plasma concentration (Tmax) Time to maximum octreotide plasma concentration (Tmax) of Octreotide Pre-dose, 0.5 hour, 1 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour, 48 hour, 96 hour, 168 hour, 336 hour, 576 hour, 1008 hour, 1416 hour.
Secondary Terminal elimination half-life (t1/2) Plasma decay half-life is the time measured for the octreotide plasma concentration to decrease by one half. Pre-dose, 0.5 hour, 1 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour, 48 hour, 96 hour, 168 hour, 336 hour, 576 hour, 1008 hour, 1416 hour.
Secondary Apparent systemic clearance (CL/F) CL/F is the volume of plasma cleared of octreotide per unit time. Pre-dose, 0.5 hour, 1 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour, 48 hour, 96 hour, 168 hour, 336 hour, 576 hour, 1008 hour, 1416 hour.
Secondary Apparent volume of distribution (Vz/F) Vz/F is the apparent volume of distribution of octreotide during the terminal elimination phase . Pre-dose, 0.5 hour, 1 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour, 48 hour, 96 hour, 168 hour, 336 hour, 576 hour, 1008 hour, 1416 hour.
Secondary Insulin-like growth factor-1 (IGF-1) concentrations over time. IGF-1 levels will be collected over time to compare the suppressive ability of octreotide. Pre-dose, 1 hour, 4 hour, 12 hour, 24 hour, 48 hour, 96 hour, 168 hour, 336 hour, 576 hour, 1008 hour, 1416 hour.
See also
  Status Clinical Trial Phase
Recruiting NCT06344650 - Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
Active, not recruiting NCT02092129 - Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. N/A
Completed NCT02012127 - Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
Active, not recruiting NCT01265121 - Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism. N/A
Terminated NCT00765323 - Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly Phase 3
Completed NCT00531908 - Physiopathology of Sodium Retention in Acromegaly N/A
Completed NCT00500227 - Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
Completed NCT01278342 - Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Phase 4
Active, not recruiting NCT01809808 - A Prospective Study of Outcome After Therapy for Acromegaly
Completed NCT00145405 - Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Phase 4
Completed NCT00210457 - Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Phase 3
Recruiting NCT05401084 - Diet in the Management of Acromegaly N/A
Recruiting NCT00005100 - Measurement of Outcome of Surgical Treatment in Patients With Acromegaly N/A
Completed NCT00521300 - Preoperative Octreotide Treatment of Acromegaly Phase 4
Completed NCT03548415 - Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands Phase 2
Not yet recruiting NCT04066569 - Reproducibility and Utility of OGTT in Acromegaly N/A
Not yet recruiting NCT05298891 - Hypoproteic Diet in Acromegaly N/A
Recruiting NCT04520646 - A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy N/A
Not yet recruiting NCT04529356 - The TMS Treatment for Postoperative Headache in GH Tumor N/A
Active, not recruiting NCT03252353 - Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly Phase 3